SC
CLYM

Samlyn Capital’s Climb Bio CLYM Stock Holding History

Samlyn Capital’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,130,237
Closed -$17.9M – 127
2022
Q1 		$17.9M Buy
2,130,237
+426,691
+25% +$3.98M 0.26% 79
2021
Q4 		$17.8M Buy
1,703,546
+22,521
+1% +$336K 0.25% 78
2021
Q3 		$30.2M Buy
+1,681,025
New +$34.7M 0.4% 64

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Samlyn Capital's CLYM Position: Q2 2022 in Review

Samlyn Capital sold out of Climb Bio (CLYM) in Q2 2022, closing a stake of 2,130,237 shares — an estimated $17.9M sold.

Samlyn Capital first reported a position in CLYM in Q3 2021 and held it in 3 quarters. The position peaked at $30.2M in Q3 2021. 29 funds tracked by Wall St. Rank hold CLYM as of Q2 2022.

  • Samlyn Capital reported no remaining Climb Bio position as of Q2 2022 after selling out during the quarter.
  • Samlyn Capital sold 2,130,237 Climb Bio shares in Q2 2022, an estimated $17.9M.
  • Samlyn Capital first reported a position in Climb Bio in Q3 2021 and held it in 3 quarters.
  • Samlyn Capital's Climb Bio position peaked at $30.2M in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Climb Bio as of Q2 2022.

Based on Samlyn Capital's 13F filing for Q2 2022, filed 15 Aug 2022.